Stockscreener 앱 받기
7.36
0.94%
-0.07
시장 영업 전:
7.36
전일 마감가:
$7.43
열려 있는:
$7.49
하루 거래량:
1.30M
Relative Volume:
0.41
시가총액:
$579.89M
수익:
$65,400
순이익/손실:
$-46.34M
주가수익비율:
-8.00
EPS:
-0.92
순현금흐름:
$-38.74M
1주 성능:
+0.14%
1개월 성능:
+2.94%
6개월 성능:
-36.00%
1년 성능:
-26.40%
1일 변동 폭
$7.29
$7.52
1주일 범위
$7.29
$7.85
52주 변동 폭
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.36 | 585.40M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2025-06-30 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
CorMedix Buyback And Melinta Integration Reframe Anti Infectives Growth Story - Yahoo Finance
Aug Wrap: What makes CorMedix Inc stock attractive todayMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
CorMedix to Participate in Upcoming Investor Conferences - GlobeNewswire
CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback - MSN
CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback - Insider Monkey
Citizens reiterates Market Outperform rating on CorMedix stock By Investing.com - Investing.com Canada
Why is CorMedix Inc stock going downWeekly Gains Report & Free Community Supported Trade Ideas - baoquankhu1.vn
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside - Yahoo Finance
Analyst Expectations For Cormedix's Future - Benzinga
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Why CorMedix could be the biopharma name to watch early in 2026 - MSN
Cormedix Inc (CRMD) Live Share Price, Invest From India - INDmoney
EV Market: What makes CorMedix Inc stock attractive todayTrade Exit Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35% - simplywall.st
CorMedix Inc. (CRMD) Stock Analysis: A Biotech Company with Over 100% Potential Upside - DirectorsTalk Interviews
CorMedix sets $75M stock buyback plan - MSN
CorMedix stock rises after announcing $75 million share buyback plan By Investing.com - Investing.com South Africa
CorMedix stock rises after announcing $75 million share buyback plan - Investing.com
CorMedix announces $75 million share repurchase program By Investing.com - Investing.com Canada
CorMedix Announces $75 Mln Share Buyback Program - Nasdaq
CorMedix Therapeutics Announces Share Repurchase Program - The Manila Times
Setup Watch: Is CorMedix Inc benefiting from interest rate changesAnalyst Downgrade & Reliable Trade Execution Plans - baoquankhu1.vn
Assessing CorMedix (CRMD) Valuation After Recent Share Price Pressure And Long Term Gains - Yahoo Finance
CorMedix Analyst Day To Clarify REZZAYO And DefenCath Phase III Path - Yahoo Finance
H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance - Finviz
CorMedix Inc. (CRMD) Stock Analysis: Exploring an 85% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock? - Finviz
Risk Check: Can SPNT expand its profit margins2025 Investor Takeaways & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
What is the long term forecast for CorMedix Inc. stockTrade Performance Summary & Daily Momentum Trading Reports - Mfd.ru
Market Leaders: Will CorMedix Inc benefit from seasonality2025 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 - marketscreener.com
Will CRMD's bearish 2026 view impact DefenCath's long-term adoption? - MSN
Published on: 2026-01-26 05:38:56 - baoquankhu1.vn
Is CorMedix (CRMD) A Potential Opportunity After Recent Share Price Volatility? - simplywall.st
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $13 - 富途牛牛
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? - Yahoo Finance
CorMedix director Dillione sells $68,800 in shares By Investing.com - Investing.com Nigeria
CorMedix director Dillione sells $68,800 in shares - Investing.com
Guidance Update: What is the next catalyst for Pyxis Tankers Inc Equity WarrantWeekly Trade Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Where Cormedix Stands With Analysts - Benzinga
RBC Capital Lowers Price Target for CRMD, Maintains Outperform R - GuruFocus
CorMedix (CRMD) price target decreased by 11.28% to 17.19 - MSN
CorMedix Investors Seek First OK Of Governance Reform Deal - Law360
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):